<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Headache and Pain</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1129-2369</issn>
      <issn pub-type="epub">1129-2377</issn>
      <publisher>
        <publisher-name>Springer Milan</publisher-name>
        <publisher-loc>Milan</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26969187</article-id>
      <article-id pub-id-type="pmc">4788665</article-id>
      <article-id pub-id-type="publisher-id">614</article-id>
      <article-id pub-id-type="doi">10.1186/s10194-016-0614-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Chronic cluster headache and the pituitary gland</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>De Pue</surname>
            <given-names>Annelien</given-names>
          </name>
          <address>
            <email>annelien.depue@Ugent.be</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lutin</surname>
            <given-names>Bart</given-names>
          </name>
          <address>
            <email>bart.lutin@gmail.com</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paemeleire</surname>
            <given-names>Koen</given-names>
          </name>
          <address>
            <phone>+32 9 332 4539</phone>
            <email>koen.paemeleire@uzgent.be</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Neurology, Ghent University Hospital, De Pintelaan 185, B-9000 Ghent, Belgium </aff>
        <aff id="Aff2"><label/>Department of Radiology, Ghent University Hospital, Ghent, Belgium </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>11</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2016</year>
      </pub-date>
      <volume>17</volume>
      <elocation-id>23</elocation-id>
      <history>
        <date date-type="received">
          <day>14</day>
          <month>1</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>3</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; De Pue et al. 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Cluster headache is classified as a primary headache by definition not caused by an underlying pathology. However, symptomatic cases of otherwise typical cluster headache have been reported.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>A 47-year-old male suffered from primary chronic cluster headache (CCH, ICHD-3 beta criteria fulfilled) since the age of 35&#xA0;years. A magnetic resonance imaging (MRI) study of the brain in 2006 came back normal. He tried several prophylactic treatments but was never longer than 1&#xA0;month without attacks. He was under chronic treatment with verapamil with only a limited effect on the attack frequency. Subcutaneous sumatriptan 6&#xA0;mg injections were very effective in aborting attacks. By February 2014 the patient developed a continuous interictal pain ipsilateral to the right-sided cluster headache attacks. An indomethacin test (up to 225&#xA0;mg/day orally) was negative. Because of the change in headache pattern we performed a new brain MRI, which showed a cystic structure in the pituitary gland. The differential diagnosis was between a Rathke cleft cyst and a cystic adenoma. Pituitary function tests showed an elevated serum prolactin level. A dopamine agonist (cabergoline) was started and the headache subsided completely. Potential pathophysiological mechanisms of pituitary tumor-associated headache are discussed.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Neuroimaging should be considered in all patients with CCH, especially those with an atypical presentation or evolution. Response to acute treatment does not exclude a secondary form of cluster headache. There may be shared pathophysiological mechanisms of primary and secondary cluster headache.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Cluster headache</kwd>
        <kwd>Pituitary gland</kwd>
        <kwd>Secondary headache</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Cluster headache (CH) is classified as a primary headache by definition not caused by an underlying pathology. However, numerous symptomatic cases of otherwise typical CH have been reported. We want to report a case of a man with typical chronic cluster headache (CCH) and a pituitary lesion only found on repeat MRI. Potential mechanisms underlying this association are discussed. We hope this will be useful to other clinicians taking care of patients suffering from this devastating condition [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 47&#xA0;year-old man was diagnosed with CH at the age of 35. A 1,5 Tesla MRI of the brain in another hospital was reportedly normal. The patient came under our care in 2011. The headache attacks and pattern were compatible with a primary CCH diagnosis according to the criteria of the International Headache Society (ICHD-3 beta, 3.1.2) [<xref ref-type="bibr" rid="CR2">2</xref>]. The patient described attacks of strictly right-sided orbitotemporal headache associated with ipsilateral tearing and nasal congestion. The attacks lasted from 20 to 60&#xA0;min, with a frequency up to 4 attacks per day, often including one attack at night. The most consistent trigger was alcohol intake. Subcutaneous sumatriptan 6&#xA0;mg injections were very effective in aborting attacks, inhaled high-flow oxygen was not. Despite different prophylactic treatments (verapamil up to 480&#xA0;mg/day, lithium up to 800&#xA0;mg/day, topiramate up to 400&#xA0;mg/day) the patient was never longer than 1&#xA0;month without attacks. By February 2014 the patient developed a continuous interictal pain ipsilateral to the right-sided CH attacks. At that point in time he was under chronic treatment with verapamil (maximal tolerated dose of 560&#xA0;mg/day) for 6&#xA0;months with only a mild effect on attack frequency. An indomethacin test (up to 225&#xA0;mg/day orally) was negative. Because of the change in headache pattern we decided to perform a new brain MRI, which showed a cystic structure in the pituitary gland (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The differential diagnosis was between a Rathke&#x2019;s cleft cyst or a cystic adenoma. Pituitary function tests (PFTs) came back normal, except for an elevated prolactin level (68.4&#xA0;&#x3BC;g/L, normal values 4&#x2013;17&#xA0;&#x3BC;g/L) and a low free testosterone level (4.44&#xA0;ng/dL, normal values 6&#x2013;25&#xA0;ng/dL). This could be due to verapamil-induced hyperprolactinemia or a prolactinoma. There was no galactorrhea, gynaecomastia, or erectile dysfunction (but he acknowledged a low libido), and visual fields were full. The patient was not willing to stop the treatment with verapamil as he feared an increase in cluster attack frequency. The patient was referred to an endocrinologist, who started carbergoline, a dopamine agonist, at a dose of 0,25&#xA0;mg twice a week. Within a few weeks after the start of the cabergoline treatment the CH attacks subsided completely and verapamil could be successfully stopped. The serum prolactin and testosterone levels normalized. A repeat MRI in October 2015 demonstrated a 30&#xA0;% reduction in size of the cystic pituitary lesion. At present the patient has been on carbergoline treatment for 1,5&#xA0;year and the cluster headaches haven&#x2019;t returned ever since and prolactin levels remained within normal range. Interestingly, the patient reports to experience a new type of unilateral frontotemporal headache attacks since about 6&#xA0;months. These attacks are milder and shortlasting (seconds), and the pain is rather stabbing. There are no associated cranial autonomic symptoms. These attacks are not disabling and the patient does not need treatment for them. We have labeled these probable short-lasting unilateral neuralgiform headache attacks (ICHDI-3 beta, 3.5.3) within the given context.<fig id="Fig1"><label>Fig. 1</label><caption><p>MRI of the pituitary gland. T1 contrast-enhanced images. <italic>Left</italic> image: sagittal view. <italic>Right</italic> image: coronal view. <italic>White</italic> arrow indicates cystic structure in the pituitary</p></caption><graphic xlink:href="10194_2016_614_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec3">
      <title>Discussion</title>
      <sec id="Sec4">
        <title>Secondary cluster headache</title>
        <p>The lesion in the pituitary and the headaches could just be a co-occurrence. However the temporal relationship between the initiation of carbergoline treatment and disappearance of the cluster headache attacks suggests a potential causal relationship with the pituitary lesion and (worsening of) the headache condition. This adds to numerous recent reports of secondary cluster-like headache (CLH). By definition before concluding to a primary headache potential causative disorders should be excluded to rule out a secondary CLH. Edvardsson reviewed 63 cases of symptomatic CH associated with vascular problems (44&#xA0;%), tumours (40&#xA0;%) or inflammation/infection (11&#xA0;%) [<xref ref-type="bibr" rid="CR3">3</xref>]. Of the 63 cases 48&#xA0;% fulfilled the criteria for CH. A larger cohort of 156 cases of CLH showed a similar distribution of causative disorders [<xref ref-type="bibr" rid="CR4">4</xref>]. On first observation, 50&#xA0;% of CLH perfectly mimicked CH at presentation [<xref ref-type="bibr" rid="CR5">5</xref>]. Furthermore, the response to typical CH medications does not exclude a secondary form. Red flags could be older age at onset, abnormalduration/frequency/localization, change in clinical characteristics or response to treatment, or an abnormal neurological/general examination [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. These findings suggest that neuroimaging should be considered in all patients with CH, even typical cases. The ICHDIII beta criteria for secondary headache disorders require evidence of causation, which includes that &#x2018;headache has significantly worsened in parallel with worsening of the presumed causative disorder&#x2019; and &#x2018;headache has significantly improved (or disappeared) in parallel with improvement of the presumed causative disorder&#x2019;. In our patient neuro-imaging was done early in his headache trajectory and results came back normal. However, in retrospect we noted that the spatial resolution of the initial MRI of the brain at the level of the pituitary gland was too low to exclude that the cystic structure (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) was already present. Even though interictal headache in cluster headache is not an uncommon phenomenon [<xref ref-type="bibr" rid="CR6">6</xref>], it was the change in headache history in our patient that sparked repeat neuro-imaging.</p>
      </sec>
      <sec id="Sec5">
        <title>Pathophysiology</title>
        <p>The pathophysiology of secondary CLH associated with pituitary disorders is not well-known. A few hypotheses are considered and summarized in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>. The long-held theory that CH was the related to a cerebrovascular problem radically changed in the late nineties with CH attacks being recoined as neurovascular in origin and with an important role for the hypothalamic-pituitary axis in the generation of these attacks. Functional imaging studies (fMRI, PET), neuro-endocrine changes (melatonin, cortisol, testosterone, &#x2026;) and the circadian/circannual rhythmicity all point to an alteration in the hypothalamus [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR10">10</xref>]. Also lithium, which is one of the known preventative treatment options for CH, is heterogeneously distributed in the brain and seems to accumulate in the hypothalamus and pituitary gland [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The pain during cluster headache attacks is attributed to activation of the trigeminovascular system and cranial autonomic symptoms are generated via the trigeminal-autonomic reflex [<xref ref-type="bibr" rid="CR13">13</xref>&#x2013;<xref ref-type="bibr" rid="CR15">15</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Potential pathophysiological links with the pituitary gland in cluster headache. (+) arguments pro (-) arguments con. &#x201C;Size is not everything&#x201D; is a reference to an article of Levy et al. [<xref ref-type="bibr" rid="CR16">16</xref>]. V1 is the ophthalmic branch of the trigeminal nerve. HPA&#x2009;=&#x2009;hypothalamic-pituitary axis. The figure is further explained in the text under the heading &#x201C;pathophysiology&#x201D;</p></caption><graphic xlink:href="10194_2016_614_Fig2_HTML" id="MO2"/></fig></p>
        <p>A structural lesion in the hypothalamic-pituitary axis could lead to an autonomic imbalance resulting in an attack-wise presentation of complaints. Others have suggested that the headache due to a lesion in the pituitary is a result of dura mater stretch or invasion of the cavernous sinus. Indeed, the cavernous sinus lateral to the sella turcica contains the ophthalmic and maxillary branches of the trigeminal nerve as well as the internal carotid artery, which are structures that can generate pain. However, in a systematic study of headache in patients with pituitary tumors, no correlation between pituitary volume and headache or between headache and cavernous sinus invasion was found [<xref ref-type="bibr" rid="CR16">16</xref>]. Pituitary tumor-associated headache may have a biochemical-neuroendocrine basis rather than a structural one [<xref ref-type="bibr" rid="CR16">16</xref>]. Finally, there is some evidence for the role of &#x201C;nociceptive peptides&#x201D; [<xref ref-type="bibr" rid="CR17">17</xref>]. The presence of calcitonin gene related peptide (CGRP) or substance P in pituitary tumors does not seem to be associated with headache [<xref ref-type="bibr" rid="CR15">15</xref>]. Other candidate peptides are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating protein and neuropeptide Y.</p>
      </sec>
      <sec id="Sec6">
        <title>Pituitary function tests, prolactin and dopamine agonist</title>
        <p>A few additional questions are provoked by this case. Is the raised serum prolactin level due to the lesion in the pituitary or induced by the high dose of verapamil? Is the effect of cabergoline proving that the lesion is a prolactinoma and the cause of the headache? Is the positive effect of carbergoline due to the normalization of serum prolactin? Is there a need for screening with PFT&#x2019;s in CH?</p>
        <p>There are physiologic, pituitary and systemic (including medications, such as verapamil) causes of hyperprolactinemia [<xref ref-type="bibr" rid="CR18">18</xref>]. Pituitary causes include prolactin-secreting pituitary adenoma or disconnection hyperprolactinemia due to a lesion that compresses the pituitary stalk [<xref ref-type="bibr" rid="CR18">18</xref>]. L-type calcium channel blockers, such as verapamil, are known to cause a doubling of serum prolactin levels [<xref ref-type="bibr" rid="CR19">19</xref>]. Since the patient was reluctant to stop verapamil because of fear increased CH attack frequency, we could not distinguish between both mechanisms prior to initiation of cabergoline treatment. Cabergoline is a long acting D2 dopamine receptor agonist that inhibits prolactin secretion. There are reported cases of microprolactinomas manifesting with headache that resolved after administration of a dopamine agonist [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], but there are also reports stating the opposite [<xref ref-type="bibr" rid="CR22">22</xref>]. The effect of cabergoline on headache doesn&#x2019;t seem to be associated with the normalization of serum prolactin [<xref ref-type="bibr" rid="CR20">20</xref>]. Potential mechanisms include alterations to the pain-modulating dopaminergic system and carbergoline, an ergot derivative, also possesses significant affinity for certain subtypes of serotonergic and adrenergic receptors. A normal MRI of the brain does not exclude a microadenoma [<xref ref-type="bibr" rid="CR23">23</xref>], and PFT&#x2019;s should therefore be considered in (refractory) patients with CCH or other (TAC).</p>
      </sec>
    </sec>
    <sec id="Sec7">
      <title>Conclusion</title>
      <p>Neuroimaging should be considered in all patients with CCH, especially those with an atypical presentation or evolution. When performing brain imaging it seems important to pay extra attention to the pituitary/parasellar region. Response to acute treatment does not exclude a secondary form of CH. PFTs should be considered in patients suffering from (refractory) CCH or other TACs. Cabergoline may have a dramatic effect on CH in patients with coexistent hyperprolactinemia.</p>
      <sec id="Sec8">
        <title>Consent</title>
        <p>The patient gave written informed consent to have his case published.</p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CCH</term>
          <def>
            <p>chronic cluster headache</p>
          </def>
        </def-item>
        <def-item>
          <term>CGRP</term>
          <def>
            <p>calcitonin gene-related peptide</p>
          </def>
        </def-item>
        <def-item>
          <term>CH</term>
          <def>
            <p>cluster headache</p>
          </def>
        </def-item>
        <def-item>
          <term>CLH</term>
          <def>
            <p>cluster-like headache</p>
          </def>
        </def-item>
        <def-item>
          <term>ICHD-3 beta</term>
          <def>
            <p>The International Classification of Headache Disorders Third Edition, beta version</p>
          </def>
        </def-item>
        <def-item>
          <term>mg</term>
          <def>
            <p>milligram</p>
          </def>
        </def-item>
        <def-item>
          <term>MRI</term>
          <def>
            <p>magnetic resonance imaging</p>
          </def>
        </def-item>
        <def-item>
          <term>ng/dl</term>
          <def>
            <p>nanogram per deciliter</p>
          </def>
        </def-item>
        <def-item>
          <term>PFT</term>
          <def>
            <p>pituitary function tests</p>
          </def>
        </def-item>
        <def-item>
          <term>TAC</term>
          <def>
            <p>trigeminal autonomic cephalalgias</p>
          </def>
        </def-item>
        <def-item>
          <term>TCC</term>
          <def>
            <p>trigeminocervical complex</p>
          </def>
        </def-item>
        <def-item>
          <term>VIP</term>
          <def>
            <p>vasoactive intestinal peptide</p>
          </def>
        </def-item>
        <def-item>
          <term>&#x3BC;g/l</term>
          <def>
            <p>microgram per liter</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Author&#x2019;s contributions</bold>
        </p>
        <p>ADP drafted the manuscript and made Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>. BL provided the MRI images. KP had substantial contribution to the manuscript and its content. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marteletti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mitsikostas</surname>
              <given-names>D-D</given-names>
            </name>
          </person-group>
          <article-title>Cluster headache: a quasi-rare disorder needing reappraisal</article-title>
          <source>J Headache Pain</source>
          <year>2015</year>
          <volume>16</volume>
          <fpage>59</fpage>
          <pub-id pub-id-type="doi">10.1186/s10194-015-0545-1</pub-id>
          <pub-id pub-id-type="pmid">26113477</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>Headache Classification Committee of the International Headache Society (IHS)</collab>
          </person-group>
          <article-title>The International classification of headache disorders, 3rd Edition (beta version)</article-title>
          <source>Cephalalgia</source>
          <year>2013</year>
          <volume>33</volume>
          <issue>9</issue>
          <fpage>629</fpage>
          <lpage>808</lpage>
          <pub-id pub-id-type="doi">10.1177/0333102413485658</pub-id>
          <pub-id pub-id-type="pmid">23771276</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edvardsson</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Symptomatic cluster headache: a review of 63 cases</article-title>
          <source>Springer Plus</source>
          <year>2014</year>
          <volume>3</volume>
          <fpage>64</fpage>
          <pub-id pub-id-type="doi">10.1186/2193-1801-3-64</pub-id>
          <pub-id pub-id-type="pmid">24570848</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mainardi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Trucco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Maggioni</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Cluster-like headache. A comprehensive reappraisal</article-title>
          <source>Cephalalgia</source>
          <year>2010</year>
          <volume>30</volume>
          <fpage>399</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="pmid">19735480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wilbrink</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Kruit</surname>
              <given-names>MC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neuro-imaging in trigeminal autonomic cephalgias : when, how, and of what?</article-title>
          <source>Curr Opinion Neurol</source>
          <year>2009</year>
          <volume>22</volume>
          <issue>3</issue>
          <fpage>247</fpage>
          <lpage>253</lpage>
          <pub-id pub-id-type="doi">10.1097/WCO.0b013e32832b4bb3</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marmura</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Pello</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
          <article-title>Interictal pain in cluster headache</article-title>
          <source>Cephalalgia</source>
          <year>2010</year>
          <volume>30</volume>
          <issue>12</issue>
          <fpage>1531</fpage>
          <lpage>1534</lpage>
          <pub-id pub-id-type="doi">10.1177/0333102410372423</pub-id>
          <pub-id pub-id-type="pmid">20974600</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bahra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buchel</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hypothalamic activation in cluster headache attacks</article-title>
          <source>Lancet</source>
          <year>1998</year>
          <volume>351</volume>
          <fpage>275</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(98)02470-2</pub-id>
          <pub-id pub-id-type="pmid">9457110</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sprenger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Boecker</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tolle</surname>
              <given-names>TR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Specific hypothalamic activation during a spontaneous cluster headache attack</article-title>
          <source>Neurology</source>
          <year>2004</year>
          <volume>62</volume>
          <fpage>516</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="doi">10.1212/WNL.62.3.516</pub-id>
          <pub-id pub-id-type="pmid">14872051</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morelli</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Pesaresi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cafforio</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Functional magnetic resonance imaging in episodic cluster headache</article-title>
          <source>J Headache Pain</source>
          <year>2008</year>
          <volume>10</volume>
          <fpage>11</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1007/s10194-008-0085-z</pub-id>
          <pub-id pub-id-type="pmid">19083151</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leone</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bussone</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>A review of hormonal findings in cluster headache. Evidence for hypothalamic involvement</article-title>
          <source>Cephalalgia</source>
          <year>1993</year>
          <volume>13</volume>
          <fpage>309</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.1993.1305309.x</pub-id>
          <pub-id pub-id-type="pmid">8242722</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edelfors</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gothgen</surname>
              <given-names>I</given-names>
            </name>
          </person-group>
          <article-title>Distribution of electrolytes within the brain in lithium treated rats</article-title>
          <source>Acta Pharmacol Toxicol</source>
          <year>1971</year>
          <volume>29</volume>
          <issue>4</issue>
          <fpage>11</fpage>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pfeifer</surname>
              <given-names>WD</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>van der Velde</surname>
              <given-names>CD</given-names>
            </name>
          </person-group>
          <article-title>Lithium accumulation in some endocrine tissues</article-title>
          <source>Acta Biol Med Ger</source>
          <year>1976</year>
          <volume>35</volume>
          <issue>11</issue>
          <fpage>1519</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">1022135</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Cluster headache: pathogenesis, diagnosis, and management</article-title>
          <source>Lancet Neurol</source>
          <year>2005</year>
          <volume>366</volume>
          <fpage>843</fpage>
          <lpage>855</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67217-0</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goadsby</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Pathophysiology of cluster headache: a trigeminal autonomic cephalgia</article-title>
          <source>Lancet Neurol</source>
          <year>2002</year>
          <volume>1</volume>
          <fpage>251</fpage>
          <lpage>257</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(02)00104-7</pub-id>
          <pub-id pub-id-type="pmid">12849458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nesbitt</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Goadsby</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Cluster headache</article-title>
          <source>BMJ</source>
          <year>2012</year>
          <volume>344</volume>
          <fpage>37</fpage>
          <lpage>42</lpage>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>J&#xE4;ger</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pituitary volume and headache &#x2013; size is not everything</article-title>
          <source>Arch Neurol</source>
          <year>2004</year>
          <volume>61</volume>
          <fpage>721</fpage>
          <lpage>725</lpage>
          <pub-id pub-id-type="doi">10.1001/archneur.61.5.721</pub-id>
          <pub-id pub-id-type="pmid">15148150</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Classey</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Maneesri</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Meeran</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Powell</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Goadsby</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>The association between calcitonin gene-related peptide (CGRP), substance P and headache in pituitary tumours</article-title>
          <source>Pituitary</source>
          <year>2004</year>
          <volume>7</volume>
          <issue>2</issue>
          <fpage>67</fpage>
          <lpage>71</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-005-5347-z</pub-id>
          <pub-id pub-id-type="pmid">15761654</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tritos</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Klibanski</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Hyperprolactinemia</article-title>
          <source>JAMA</source>
          <year>2015</year>
          <volume>314</volume>
          <issue>16</issue>
          <fpage>1742</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2015.7871</pub-id>
          <pub-id pub-id-type="pmid">26505599</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kelley</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Kamal</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Molitch</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Mechanism of verapamil calcium channel blockade-induced hyperprolactinemia</article-title>
          <source>Am J Physiol</source>
          <year>1996</year>
          <volume>270</volume>
          <issue>1 Pt 1</issue>
          <fpage>E96</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">8772480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kallestrup</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Kasch</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>&#xD6;sterby</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Prolactinoma-associated headache and dopamine agonist treatment</article-title>
          <source>Cephalalgia</source>
          <year>2014</year>
          <volume>34</volume>
          <issue>7</issue>
          <fpage>493</fpage>
          <lpage>502</lpage>
          <pub-id pub-id-type="doi">10.1177/0333102413515343</pub-id>
          <pub-id pub-id-type="pmid">24351278</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gabrielli</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gasbarrini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fiore</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Resolution of migraine with aura after successful treatment of a pituitary microadenoma</article-title>
          <source>Cephalalgia</source>
          <year>2002</year>
          <volume>22</volume>
          <fpage>149</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00314.x</pub-id>
          <pub-id pub-id-type="pmid">11972585</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matharu</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Goadsby</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Prolactinomas, dopamine agonist and headache: two case reports</article-title>
          <source>Eur J Neurol</source>
          <year>2003</year>
          <volume>10</volume>
          <fpage>169</fpage>
          <lpage>174</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1468-1331.2003.00549.x</pub-id>
          <pub-id pub-id-type="pmid">12603293</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hauache</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Maia</surname>
              <given-names>AC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Screening for macroprolactinaemia and pituitary imaging studies</article-title>
          <source>Clin Endocrinol (Osf)</source>
          <year>2002</year>
          <volume>57</volume>
          <issue>3</issue>
          <fpage>327</fpage>
          <lpage>331</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2265.2002.01586.x</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
